FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023241971> ?p ?o ?g. }

• W2023241971 endingPage "121" @default.
• W2023241971 startingPage "115" @default.
• W2023241971 abstract "ObjectiveTreosulfan is a prodrug with a specific clinical activity in ovarian carcinoma and other solid tumors. Due to its myeloablative and immunosuppressive effects, its use in conditioning regimens prior to allogeneic stem cell treatment (SCT) has been proposed. In the present preclinical study, myeloablative as well as immunosuppressive properties of treosulfan were compared with those of busulfan and cyclophosphamide.MethodsThree groups of BALB/c mice were treated with treosulfan, cyclophosphamide, or busulfan at sublethal doses that maintained survival without bone marrow support. The control group was left untreated. At different intervals, colony-forming unit granulocyte macrophage assay was performed on marrow cells. Additionally, immunological analyses were performed using spleen cells.ResultsWe found that treosulfan and busulfan induced a high and persisting degree of myeloablation, as compared with cyclophosphamide. Moreover, treosulfan was more effective in depletion of splenic B and T cells in comparison with busulfan and cyclophosphamide. Furthermore, T cells isolated from the spleens of treosulfan- or busulfan-treated mice were not responsive to allogeneic cells compared with that observed in controls and cyclophosphamide-treated mice. Treatment with treosulfan induced only interleukin-2 production in spleen cells for a short time and had no significant effect on synthesis of tumor necrosis factor-α and/or interferon-γ as compared with that observed in splenic T cells isolated from mice treated with either busulfan or cyclophosphamide.ConclusionOur findings suggest that treosulfan possesses both myeloablative and immunosuppressive properties and may be used as a single agent for conditioning prior to bone marrow transplantation. Treosulfan is a prodrug with a specific clinical activity in ovarian carcinoma and other solid tumors. Due to its myeloablative and immunosuppressive effects, its use in conditioning regimens prior to allogeneic stem cell treatment (SCT) has been proposed. In the present preclinical study, myeloablative as well as immunosuppressive properties of treosulfan were compared with those of busulfan and cyclophosphamide. Three groups of BALB/c mice were treated with treosulfan, cyclophosphamide, or busulfan at sublethal doses that maintained survival without bone marrow support. The control group was left untreated. At different intervals, colony-forming unit granulocyte macrophage assay was performed on marrow cells. Additionally, immunological analyses were performed using spleen cells. We found that treosulfan and busulfan induced a high and persisting degree of myeloablation, as compared with cyclophosphamide. Moreover, treosulfan was more effective in depletion of splenic B and T cells in comparison with busulfan and cyclophosphamide. Furthermore, T cells isolated from the spleens of treosulfan- or busulfan-treated mice were not responsive to allogeneic cells compared with that observed in controls and cyclophosphamide-treated mice. Treatment with treosulfan induced only interleukin-2 production in spleen cells for a short time and had no significant effect on synthesis of tumor necrosis factor-α and/or interferon-γ as compared with that observed in splenic T cells isolated from mice treated with either busulfan or cyclophosphamide. Our findings suggest that treosulfan possesses both myeloablative and immunosuppressive properties and may be used as a single agent for conditioning prior to bone marrow transplantation." @default.
• W2023241971 created "2016-06-24" @default.
• W2023241971 creator A5006533812 @default.
• W2023241971 creator A5007126255 @default.
• W2023241971 creator A5008700475 @default.
• W2023241971 creator A5017811270 @default.
• W2023241971 creator A5026283141 @default.
• W2023241971 creator A5039353263 @default.
• W2023241971 creator A5059684414 @default.
• W2023241971 creator A5065745451 @default.
• W2023241971 creator A5073328347 @default.
• W2023241971 creator A5075222101 @default.
• W2023241971 date "2006-01-01" @default.
• W2023241971 modified "2023-10-16" @default.
• W2023241971 title "Myeloablative and immunosuppressive properties of treosulfan in mice" @default.
• W2023241971 cites W1565345042 @default.
• W2023241971 cites W1590372766 @default.
• W2023241971 cites W193514409 @default.
• W2023241971 cites W1966355666 @default.
• W2023241971 cites W1972802508 @default.
• W2023241971 cites W1979165111 @default.
• W2023241971 cites W1982103948 @default.
• W2023241971 cites W1982560771 @default.
• W2023241971 cites W1983063582 @default.
• W2023241971 cites W2006751059 @default.
• W2023241971 cites W2009114096 @default.
• W2023241971 cites W2017094277 @default.
• W2023241971 cites W2018714108 @default.
• W2023241971 cites W2024639475 @default.
• W2023241971 cites W2028691339 @default.
• W2023241971 cites W2044794988 @default.
• W2023241971 cites W2045682738 @default.
• W2023241971 cites W2046147885 @default.
• W2023241971 cites W2048280413 @default.
• W2023241971 cites W2055472417 @default.
• W2023241971 cites W2060575426 @default.
• W2023241971 cites W2065878736 @default.
• W2023241971 cites W2068765603 @default.
• W2023241971 cites W2077999717 @default.
• W2023241971 cites W2078882111 @default.
• W2023241971 cites W2082695120 @default.
• W2023241971 cites W2088346020 @default.
• W2023241971 cites W2156369462 @default.
• W2023241971 cites W2168847627 @default.
• W2023241971 cites W2171267773 @default.
• W2023241971 cites W2312764018 @default.
• W2023241971 cites W2323339045 @default.
• W2023241971 cites W2328166681 @default.
• W2023241971 cites W2332187296 @default.
• W2023241971 cites W2339482838 @default.
• W2023241971 cites W3140738769 @default.
• W2023241971 cites W5387557 @default.
• W2023241971 doi "https://doi.org/10.1016/j.exphem.2005.09.015" @default.
• W2023241971 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16413398" @default.
• W2023241971 hasPublicationYear "2006" @default.
• W2023241971 type Work @default.
• W2023241971 sameAs 2023241971 @default.
• W2023241971 citedByCount "77" @default.
• W2023241971 countsByYear W20232419712012 @default.
• W2023241971 countsByYear W20232419712013 @default.
• W2023241971 countsByYear W20232419712014 @default.
• W2023241971 countsByYear W20232419712015 @default.
• W2023241971 countsByYear W20232419712016 @default.
• W2023241971 countsByYear W20232419712017 @default.
• W2023241971 countsByYear W20232419712018 @default.
• W2023241971 countsByYear W20232419712019 @default.
• W2023241971 countsByYear W20232419712020 @default.
• W2023241971 countsByYear W20232419712021 @default.
• W2023241971 countsByYear W20232419712022 @default.
• W2023241971 countsByYear W20232419712023 @default.
• W2023241971 crossrefType "journal-article" @default.
• W2023241971 hasAuthorship W2023241971A5006533812 @default.
• W2023241971 hasAuthorship W2023241971A5007126255 @default.
• W2023241971 hasAuthorship W2023241971A5008700475 @default.
• W2023241971 hasAuthorship W2023241971A5017811270 @default.
• W2023241971 hasAuthorship W2023241971A5026283141 @default.
• W2023241971 hasAuthorship W2023241971A5039353263 @default.
• W2023241971 hasAuthorship W2023241971A5059684414 @default.
• W2023241971 hasAuthorship W2023241971A5065745451 @default.
• W2023241971 hasAuthorship W2023241971A5073328347 @default.
• W2023241971 hasAuthorship W2023241971A5075222101 @default.
• W2023241971 hasBestOaLocation W20232419711 @default.
• W2023241971 hasConcept C126322002 @default.
• W2023241971 hasConcept C203014093 @default.
• W2023241971 hasConcept C2776694085 @default.
• W2023241971 hasConcept C2776755627 @default.
• W2023241971 hasConcept C2779178397 @default.
• W2023241971 hasConcept C2780007613 @default.
• W2023241971 hasConcept C2780611847 @default.
• W2023241971 hasConcept C2780931953 @default.
• W2023241971 hasConcept C502942594 @default.
• W2023241971 hasConcept C71924100 @default.
• W2023241971 hasConcept C98274493 @default.
• W2023241971 hasConceptScore W2023241971C126322002 @default.
• W2023241971 hasConceptScore W2023241971C203014093 @default.
• W2023241971 hasConceptScore W2023241971C2776694085 @default.
• W2023241971 hasConceptScore W2023241971C2776755627 @default.
• W2023241971 hasConceptScore W2023241971C2779178397 @default.

• next